Lysando AG Strengthens Board of Directors by Appointment of Mr. Sang Jung Kim
“A few months after the start of our strategic partnership with AMICOGEN, the Board of Lysando is further strengthened. Sang Jung Kim and AMICOGEN share our entrepreneurial spirit and goal to prevent the antibiotic Armageddeon," says the Chairman of the Board of Lysando AG, Count Markus Matuschka de Greiffenclau.
“For AMICOGEN and for me, strategic partnership is not just an empty phrase: it is the commitment to a close shoulder-to-shoulder relationship. I am convinced that the great Lysando Artilysin® technology with AMICOGEN and combined forces will win the fight against resistant bacteria and for a healthy microbiome", states Sang Jung Kim.
The Board of Directors officially added Sang Jung Kim on 1st February 2022.
About Lysando AG
Lysando AG is the market-leader for antimicrobial proteins, so-called Artilysin®s.
Artilysin®s are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly. Artilysin®s can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care.
The R&D Facility of Lysando AG is Lysando Innovations Lab GmbH located in BioPark in Regensburg. BioPark Regensburg promotes biotechnology, medical technology, diagnostics & analytics as well as the health economy of the Regensburg area.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005115/en/
Website: https://www.lysando.com/welcome.html
Contact
Lysando AG
Verena Schossmann
+41(0)79 211 83 42
Verena.Schossmann@lysando.com
